文献速递慢性肾脏病血液净化与透析

口服罗沙司他治疗日本血液透析合并贫血CKD患者的3期随机双盲阳性对照研究

Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan.
PubMed 文献 · J Am Soc Nephrol · 2020-06-03

这项3期、24周、双盲双模拟研究将303例日本血液透析合并贫血的CKD患者随机分配至口服罗沙司他每周三次组或达依泊汀α每周一次注射组,滴定剂量维持血红蛋白在10-12 g/dl。主要终点为基线至第18-24周平均血红蛋白变化(∆Hb18-24),罗沙司他与达依泊汀α的差值为-0.02 g/dl(95%CI -0.18至0.15),证实罗沙司他非劣效于达依泊汀α。罗沙司他组第18-24周平均血红蛋白为10.99 g/dl(95%CI 10.88至11.10),维持率95.2%对91.3%,不良事件与既往报告一致。

要点

  • 罗沙司他每周三次口服非劣效于达依泊汀α每周一次注射,∆Hb18-24差值为-0.02 g/dl。
  • 罗沙司他组第18-24周平均血红蛋白10.99 g/dl,维持率95.2%。
  • 铁参数在罗沙司他治疗下保持临床稳定,不良事件与既往报告一致。

核心结论

  • 罗沙司他可维持血液透析患者血红蛋白在10-12 g/dl,且非劣效于达依泊汀α。

研究设计与样本

  • 3期、24周、双盲、双模拟、阳性对照研究,随机分配303例日本血液透析合并贫血的CKD患者至罗沙司他组(n=151)或达依泊汀α组(n=152)。

主要发现

  • 罗沙司他与达依泊汀α的∆Hb18-24差值为-0.02 g/dl(95%CI -0.18至0.15),证实非劣效性。
  • 罗沙司他组第18-24周平均血红蛋白为10.99 g/dl(95%CI 10.88至11.10)。
  • 第18-24周至少有一次血红蛋白值的患者中,罗沙司他组维持率为95.2%,达依泊汀α组为91.3%。
  • 罗沙司他组血清铁、铁蛋白和转铁蛋白饱和度保持临床稳定;转铁蛋白和总铁结合力在第4周前升高后稳定。
  • 常见治疗中出现的不良事件包括鼻咽炎、分流道狭窄、腹泻、挫伤和呕吐;新发或加重视网膜出血比例罗沙司他组32.4%、达依泊汀α组36.6%。

关键数值与推荐

  • 血红蛋白目标维持范围10-12 g/dl。
  • 主要终点为非劣效性检验,差值95%CI上限低于预设非劣效界值(原文未报告具体界值)。

临床怎么用

  • 罗沙司他每周三次口服可作为血液透析合并贫血CKD患者达依泊汀α的替代方案,需滴定剂量维持血红蛋白10-12 g/dl。

局限性

  • 研究仅纳入日本血液透析患者,结论外推需谨慎。
  • 原文未报告非劣效界值、样本量估算依据及随访超过24周的数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor approved in China for dialysis-dependent CKD anemia. METHODS: This phase 3, 24-week, double-blind, double-dummy study evaluated roxadustat's noninferiority to darbepoetin alfa for hemodialysis-dependent CKD anemia. We randomly assigned Japanese patients to oral roxadustat three times weekly or to darbepoetin alfa injections once weekly, titrating doses to maintain hemoglobin between 10-12 g/dl. The primary end point was change of average hemoglobin from baseline to weeks 18-24 (∆Hb18-24). Secondary end points were average hemoglobin and proportion of patients with hemoglobin between 10-12 g/dl (maintenance rate) at weeks 18-24, and iron parameters. Safety assessments included treatment-emergent adverse events and adjudicated ophthalmologic findings. RESULTS: We randomly assigned 303 patients to roxadustat (n=151) or darbepoetin alfa (n=152). The difference between roxadustat and darbepoetin alfa in ∆Hb18-24 was -0.02 g/dl (95% confidence interval, -0.18 to 0.15), confirming roxadustat's noninferiority to darbepoetin alfa. Average hemoglobin at weeks 18-24 with roxadustat was 10.99 g/dl (95% confidence interval: 10.88 to 11.10), confirming its efficacy. Among patients with one or more hemoglobin value during weeks 18-24, the maintenance rate was 95.2% with roxadustat and 91.3% with darbepoetin alfa. Serum iron, ferritin, and transferrin saturation remained clinically stable with roxadustat; transferrin and total iron binding capacity increased through week 4 before stabilizing. Common treatment-emergent adverse events were nasopharyngitis, shunt stenosis, diarrhea, contusion, and vomiting. The proportion of patients with new or worsening retinal hemorrhage was 32.4% with roxadustat and 36.6% with darbepoetin alfa. We observed no clinically meaningful changes in retinal thickness groups. CONCLUSIONS: Roxadustat maintained hemoglobin within 10-12 g/dl in patients on hemodialysis and was noninferior to darbepoetin alfa. Treatment-emergent adverse events were consistent with previous reports. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: A Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients with Anemia, NCT02952092 (ClinicalTrials.gov).

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Akizawa T, Iwasaki M, Yamaguchi Y, et al. Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan. J Am Soc Nephrol. 2020. PMID: 32493693. doi:10.1681/ASN.2019060623

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。